Silver Elephant Announces Annual General Meeting Voting Results

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Silver Elephant Mining Corp. (TSX: ELEF) (OTC Pink: SILEF) (FSE: 1P2N) ("Silver Elephant" or the "Company") is pleased to announce that all resolutions put forward at the Annual General Meeting (the "Meeting") of the Company's shareholders held May 10, 2024, as described in the Company's information circular dated March 27, 2024 (the "Circular"), were approved. A summary of the results are set out below:

• Number of Directions: set the number of directors at four (4).

• Election of Directors: the nominees listed in the Circular the Meeting were all elected as Directors until the next annual general meeting of the Shareholders. Detailed results of the vote are set out below:

• Approved the appointment of Mao & Ying LLP, Chartered Professional Accountants as the auditors of the Company and authorizing the directors to fix the remuneration to be paid to Mao & Ying LLP, Chartered Professional Accountants.

For more information on the voting results, please see the Report of Voting Results which is available at www.sedar.com.

About Silver Elephant Mining Corp.

Silver Elephant is a silver mining company, with its flagship Pulacayo-Paca silver project in production since October 2023 in Bolivia.

Further information on Silver Elephant can be found at www.silverelef.com.

SILVER ELEPHANT MINING CORP.
ON BEHALF OF THE BOARD

"John Lee"
Executive Chairman

For more information about Silver Elephant, please contact Investor Relations:
+1.604.569.3661 ext. 101
[email protected]
www.silverelef.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209204

You May Also Be Interested In

• RalivON Makes Its Public Debut at American Dream, Bringing a New Approach to Beauty From Within to Consumers
• Dr. Ball LLC Introduces New Keynote When the Numbers Dip Leadership Rises
• Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026